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Abstract 
AIM: To evaluate hearing in β-thalassemia major patients on iron chelation therapy by using pure-tone 
audiometry (PTA) and distortion product otoacoustic emissions (DPOAE).  
SUBJECTS AND METHODS: This cross-sectional, descriptive study was done on (48) diagnosed, 6-18 years 
old, β-thalassemia major patients who had received at least 3 years iron chelating agent deferoxamine (DFO). We 
performed PTA, DPOAE testing, and tympanometry for all participants. SPSS was used to analyse data. P < 0.05 
was accepted as statistically significant. 
RESULTS: No significant difference was found between PTA and DPOAE testing in their capability to detect 
ototoxicity. PTA and DPOAE testing for the detection of ototoxicity in BTM and BTI, kappa values (κ) were found 
to be 0.516 and 0.459, respectively. The whole mean serum ferritin level was 2,251.3 ng/ml. The mean level was 
1,603 ± 1,380 ng/ml in the patients with SNHL and 2,405 ± 1,908 ng/ml in the patients with normal hearing with 
the statistically significant difference among both groups (p = 0.015). The occurrence of ototoxicity was 
statistically significant with increasing age (p < 0.001). There was no marked difference as regards gender (p = 
0.72). 
CONCLUSION: Hearing loss is prevailing in patients with β-thalassemia major on iron chelating agents. 
Therefore, regular hearing evaluations and periodic check-ups after the initiation of chelation therapy are 
mandatory. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
β-Thalassemia major is considered a critical 
health issue in both developed and developing 
countries with approximately 330,000 affected 
newborns each year. Countries of the Middle East are 
the most affected area as it is geographically located 
in the “thalassemia belt [1]. 
It is a severe hereditary transfusion 
dependent anaemia that occurs due to defects in 
haemoglobin (Hb) production [2].  
It is characterised by a marked drop in beta-
globin chains production and ineffective erythropoiesis 
with bone expansion and extramedullary 
haematopoiesis in the liver, spleen, and other sites, 
such as paravertebral masses [3].  
 Regular monthly blood transfusions are used 
to decrease the acute symptoms of the disease in 
those patients; although frequent blood transfusions 
can lead to hemosiderosis besides hepatic, cardiac 
and endocrine complications [4], [5]. In spite of the 
usefulness of chelating agents, those patients usually 
die in the second decade of life because of the 
previous complications. But nowadays, the survival 
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rate has been markedly improved due to therapy 
advances, particularly after chelation therapy. Hearing 
problems were seen in thalassemia patients on 
deferoxamine (DFO) which is known to be a natural 
substance, a metabolite of Streptomyces pilosus that 
forms a stable chelate with ferric iron [6]. Through 
time, DFO that was firstly used in 1962, has proved to 
be the most powerful iron-chelating agent available 
and was recommended for more comprehensive, 
high-dose intake due to its negligible adverse 
reactions. Ototoxicity caused by DFO was first 
reported in the 1980s [7]. Hearing complications in 
thalassemia is mostly related to chronic anaemia, iron 
overload, extramedullary hematopoiesis and adverse 
reactions of iron chelating agents.  
This study aims to evaluate the ototoxic 
effects of iron chelators in patients with β-thalassemia 
major on iron chelation therapy for more than 3 years 
regularly by using pure-tone audiometry (PTA) & 
distortion product otoacoustic emissions (DPOAE) 
and correlation of these findings with mean 
haemoglobin, ferritin level and duration of treatment. 
 
 
Subjects and Methods 
 
This cross-sectional, descriptive study was 
conducted at The Audiology Unit, El-Hussein Hospital, 
Al-Azhar University, Faculty of Medicine. A group of 
48 diagnosed β-thalassemia major patients aged 6-18 
years old who had received at least 3 years of 
treatment with an iron chelating agent deferoxamine 
(DFO) were enrolled in the study. All Routine 
haematological studies were performed according to 
conventional methods. A complete personal history 
was taken, ENT examination was performed on the 
patients. The data was collected which included 
name, age, sex, Hb, duration and dose of chelation 
therapy at the time of audiology test. Those with an 
active infection, middle ear effusion, a current or 
previous otologic disease, a tympanic membrane 
perforation, a history of ear surgery, a hearing loss 
secondary to acoustic trauma or hereditary factors 
and an inability to satisfactorily undergo audiologic 
testing were excluded from the study. 
 
Audiologic testing 
One qualified audiologist has performed PTA, 
DPOAE testing, and tympanometry for all subjects 
using the same Inter acoustics Audiometer model 
AC40, Inter acoustic Tympano meter model AZ7 and 
Distortion Evoked Otoacoustic Emission (DPOAE, 
ILO88). PTA thresholds were measured in the 
standard increments with bone conduction testing with 
tone stimulus ranging from 0.5 to 8 kHz. A threshold 
shift > 20 dB at one or more frequencies on PTA was 
considered to be significant. Two simultaneous pure-
tone signals were introduced to the ear at two different 
frequencies (f1 and f2, where f2 > f1), and the 2f1-f2 
cubic distortion-product component was recorded for 
DPOAE testing. Recordings were obtained with a 
frequency ratio of f2/f1 fixed at 1.22. Nine pairs of 
equal-level primary frequencies (Ll = L2 = 65 dB SPL) 
were used at three points per octave, spanning the f2 
frequency range from 1,001 to 6,348 Hz. The 65-dB 
levels of the primary tones were used as the stimulus 
levels that would most reliably elicit DPOAE from ears 
with hearing problems. The amplitude was determined 
for each patient. Detection thresholds were calculated 
6 dB higher than the noise floor. The accuracy of the 
calibrations had been confirmed earlier by DPOAE 
testing on 10 healthy individuals. 
Table 1: Pure tone average (PTA) of the studied group 
Frequency (Hz) Mean ± SD 
250 10.0 ± 3.2 
500 11.3 ± 2.5 
1000 12.6 ± 3.6 
2000 18.9 ± 4.1 
4000 19.2 ± 6.5 
8000 21.00 ± 8.4 
 
Statistical analysis 
Data were analysed with the Statistical 
Package for the Social Sciences, version 21 for 
Windows. Continuous data were expressed as mean 
± standard deviation and were compared by using the 
chi-square, ANOVA, and Student unpaired t-tests for 
statistical evaluation of parameters. P < 0.05 was 
accepted as statistically significant. 
 
 
Ethical Considerations 
 
The study protocol was approved by the 
Ethics Committee of the National Research Center 
under the registration number (16358). 
 
 
Results 
 
In the right ears, PTA examination at 4, 6, and 
8 kHz showed that hearing threshold levels were 
between 0 and 20 dB in 37patients (77%); in the 
remaining 11 patients (23%), sensorineural hearing 
loss (SNHL) was found at ≥ 21 dB.  
Table 2: Pure Tone Audiometry (PTA) statistics of hearing loss 
among the studied group 
 p-Value p-Value p-Value 
 4kHz 6kHz 8kHz 
 (PTA) (right) 0.547 0.764 0.712 
 (PTA) (left) 0.581 0.818 0.821 
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In the left ears, PTA at 4, 6, and 8 kHz 
revealed that hearing threshold levels were normal in 
34 patients (71%), with SNHL in the remaining 14 
patients (29%).  
Table 3: DPOAE testing results statistics of hearing loss 
among the studied group 
 p-Value p-Value p-Value 
 4kHz 6kHz 8kHz 
DPOAE (right) 0.179 0.183 0.520 
DPOAE (left) 0.927 0.915 0.478 
 
In the right ears, DPOE testing showed that 
the signal/ noise ratios at 4, 6, and 8 kHz were ≥ 6 dB 
in 36 patients (75%) and 39 patients (81%) and 9 
patients (19%).  
Table 4: Values of mean DPOAE  
 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
Side  0.5 kHz 1 kHz 2 kHz 4 kHz 6 kHz 8 kHz 
DPOAE Right  0.30 ± 6.08 7.29 ± 6.09 9.54 ± 6.45 11.94 ± 7.35 13.03 ± 10.52 12.31 ± 9.35 
DPOAE Left  0.53 ± 6.58 7.69 ± 5.49 9.69 ± 5.20 11.45 ± 7.64 14.16 ± 10.38 13.15 ± 9.27 
 
According to these results, there was no 
marked difference between PTA and DPOAE testing 
in detecting ototoxicity. For evaluation of PTA and 
DPOAE testing validity for ototoxicity detection in β-
thalassemia major patients, kappa values (κ) were 
found to be 0.516 and 0.459, respectively. Laboratory 
results are shown in (Table 5). The overall mean 
serum ferritin level was 2,251.3 ng/ml. The mean level 
was 1,603 ± 1,380 ng/ml in the patients with SNHL 
and 2,405 ± 1,908 ng/ml in the patients with normal 
hearing with a statistically significant difference 
between the two groups (p = 0.015). A statistically 
significant difference in the occurrence of ototoxicity 
was found with increasing age (p < 0.001) and no 
significant difference was found as regards gender (p 
= 0.72). 
Table 5: Laboratory investigations of the studied group 
Parameter  Range (mean) 
Hemoglobin (g/dl) 6.4 - 11.3 (8.3) 
Ferritin (ng/ml) 108 - 8,471 (2,251.3) 
Aspartate transaminase (U/L) 13 - 171 (39) 
Alanine transaminase (U/L) 6 - 310 (43) 
Total bilirubin (mg/dl) 0.38 - 10.8 (11.7) 
Direct bilirubin (mg/dl) 0.17 - 4.53 (0.605) 
 
 
 
Discussion  
 
β -thalassemia is a disorder caused by the 
reduced or absent synthesis of the beta globin chains 
of the haemoglobin tetramer (Cao and Galanello, 
2010) [8]. 
 Stem cell transplantation is effective in 
treatment, but regular transfusion is the standard 
accepted therapy which postpones ineffective 
erythropoiesis and adjusts anaemia. Hemosiderosis 
occurs secondary to a hyper transfusion therapy is the 
most dangerous side effect of chelation therapy 
(Quiralo & Vichinsky, 2004) [9]. 
Effective iron chelation therapy means 
reaching a neutral or negative iron balance, where 
excretion of iron equals or more than the rate of new 
iron accumulation. In β-thalassemia major, frequent 
red blood cell (RBC) transfusions are the main source 
of iron intake. 
Deferoxamine is the most frequently used 
agent. Ototoxicity is dose-dependent, the 
recommended therapeutic dosage is 20- 40 
mg/kg/day; studies have not shown any ototoxic side 
effect at dosages below 50 mg/kg/day (Nathan DG, 
2003) [10]. 
 Ototoxicity occurs due to damage of the 
ciliated cells of the basal turn of the cochlea, that 
causes high-frequency SNHL. Studies have 
demonstrated that the occurrence of SNHL in these 
cases ranging between 14 to 26% [11]. Shamsian et 
al., 2008 [12] estimated ototoxicity of desferrioxamine 
in 67 children with β -thalassemia major more than 5 
years using PTA where SNHL was seen in 7.4% of 
cases. Ambrosetti et al., 2000 [12] found an 
occurrence of 26.3% among 57 β -thalassemia major 
patients between 17 to 32 years, while Kontzoglou et 
al., 2004 [13] found an incidence of 20.2% among 104 
children with β -thalassemia major 6 to 35 years old. 
Karimi et al., 2002 [14] reported SNHL in more than 
half of β -thalassemia major patients on regular 
chelation treatment with deferoxamine. 
We found the occurrence of SNHL on PTA as 
39.0% in the right ear and 27.7% in the left ear. 
Onerci et al.,1994 [15] found audiology and 
impedance metric findings in 34 patients with 
thalassemia that most ears in the β -thalassemia 
major group had a conductive hearing loss or a mixed 
hearing loss and that no patient in that group had a 
pure sensorineural deficit. 
 Several authors have studied the ototoxicity 
of deferoxamine, and they reported that the hearing 
loss it is associated with is the sensorineural type and 
that it mainly affects the high frequencies [16], [17], 
[18], [19]. 
 In our study, the frequency of SNHL in 
patients on deferoxamine therapy was 26.8%, which 
is compatible with other findings in the literature.  
Estimations of otoacoustic emissions as a tool 
of reliable cochlear investigation are especially helpful 
in children [20].  
 Distortion-product emissions are the most 
frequently investigated type of otoacoustic emissions. 
DPOAE is more sensitive for monitoring of cochlear 
function. It is noninvasive, rapid, reliable and easy to 
use. DPOAE values can be reliably measured in 
nearly all human ears with normal cochlear and 
middle ear function. Their high degree of test-retest 
reliability and their accuracy and objectivity in the 
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evaluation of cochlear function (outer hair cell function 
in particular) makes them suitable for observing 
dynamic changes in cochlear responsiveness before 
they become functionally significant as a hearing loss 
[21], [22]. 
In our study, we noted a significant decrease 
in amplitude, principally in the higher frequencies (> 4 
kHz), which was agreeable with the high-frequency 
hearing loss usually seen with deferoxamine 
ototoxicity [23]. 
DPOAE has been shown to have an 
advantage over PTA as an ototoxicity screening tool, 
as DPOE amplitudes fall significantly before 
behavioural threshold changes are noted at 
corresponding frequencies on PTA [24]. 
In our study, we estimated that the 
consistency of PTA and DPOAE testing for the 
detection of ototoxicity in BTM was of a moderate 
degree — κ = 0.516. recommended dose of DFO is 
20-60 mg/kg/day with maximum dose of 50 
mg/kg/day. Individual susceptibility might augment 
liability to the ototoxic effect of chelating drugs. 
For determining hearing loss secondary to 
ototoxic drug use, PTA and DPOAE testing show a 
reasonable level of reliability. Also, it can be used for 
the early detection of SNHL. These two ways are 
associated with each other. In our study on hearing 
the loss in iron chelation therapy, we found no study 
that estimated the high frequencies. PTA has been 
investigated at frequencies up to 8 kHz [25], [26], [27]. 
 Other studies of ototoxicity have 
demonstrated that high-frequency PTA was highly 
significant in detecting threshold changes due to 
ototoxicity. Beahan et al. reported that high-frequency 
PTA was reliable in detecting ototoxicity in children 
older than 7 years old [28]. 
It was found that SNHL is not correlated 
directly to serum ferritin levels or deferoxamine 
dosage; but also, genetic and constitutional factors 
may be related [29]. 
 Porter et al., studied 47 BTM patients and 
found that high-dose deferoxamine therapy 
associated with low serum ferritin levels (< 2000 
ng/ml) is a major risk factor for deferoxamine 
ototoxicity [19]. 
 Ambrosetti et al., noted that there is no 
relationship between age, serum ferritin level, and 
therapeutic indices with hearing loss. 
In conclusion, our study confirms that iron 
chelation therapy can be a cause of ototoxicity, so, 
regular follow up of β-thalassemia patients with PTA 
and DPOAE testing is mandatory with baseline 
hearing test of cochlear function before initiation of 
chelation therapy with a target of preventing 
permanent damage. 
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